Salix Pharmaceuticals may have hit the jackpot as an unintended consequence of a drug designed to treat E.coli and diarrhea being proven to treat patients with debilitating liver disorder and brain damage caused by liver failure as well as treating for the maintenance of remission of hepatic encephalopathy (HE).
There are more than 600,000 cases of cirrhosis in the United States and it is a leading cause of death in the United States. The number of cases of liver disease in the United States and around the world is rapidly increasing, with the estimated prevalence of chronic liver disease in the United States believed to be between 6 and 7 million cases.
Salix Pharmaceuticals develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete with any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team.
Its products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis.
The company also offers Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; Apriso, for the maintenance of remission of ulcerative colitis in adults; and Colazal capsules for the treatment of ulcerative colitis.
Salix Pharmaceuticals products under development include Balsalazide Disodium tablets for ulcerative colitis; Crofelemer for HIV-associated diarrhea; Vapreotide acetate for acute esophageal variceal bleeding; and Metoclopramide-Zydis for the treatment of gastroesphageal reflux and gastroparesis.
SLXP has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; CedarsSinai Medical Center; ALW Partnership; Debiopharm Group; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC.
SLXP Investor Highlights
Reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
SLXP focuses on late-stage products serving to reduce the risk, time and expense invested compared to the investment typically associated with the research and early development phases of pharmaceutical products.
Salix focuses its investment of time and energy on maximizing the commercial potential of their products. Operations such as manufacturing are outsourced. Resources are not tied up in “bricks and mortar” but rather invested in activities directed toward increasing product sales.
Salix has a direct sales force to promote its products to the fastest-adopting, highest-prescribing physicians in the U.S. responsible for treating gastrointestinal disease.
SLXP plans to grow its business by adding new products to its portfolio by: expanding the indications for current products, in-licensing or acquiring new products and Co-promoting selected third-party products.
The U.S. represents the largest pharmaceutical market in the world. Salix markets its products to gastroenterologists in the U.S. through its own specialty sales force. Saliz will form its own strategic alliances to market products outside the U.S. in order to avoid the significant costs, risks and infrastructure inherent in assembling an international sales force.
To learn more about SLXP visit http://www.smallcapreview.com/slxp.htm
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has not been compensated for its efforts with regards to Salix Pharmaceuticals.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/.
